GE teams with Austrian research centre to optimise cell line selection

By Dan Stanton contact

- Last updated on GMT

Image c/o GE Healthcare
Image c/o GE Healthcare

Related tags: Cell line, Cell culture, Chinese hamster ovary cell

GE Healthcare has teamed up with the Austrian Centre of Industrial Biotechnology (acib) in an effort to remove trial and error from the cell line optimization process.

The three-year partnership will identify tools and methods to modify and optimise Chinese hamster ovary (CHO) cell line performance using GE Healthcare’s vector solutions and cell culture medium.

“We aim to find ways to improve the bioprocess relevant global phenotype or molecular machinery of host cells by tuning multiple cellular pathways simultaneously, and hence the activity of many individual genes,”​ Morgan Norris, general manager of Upstream and Cell Culture at GE Healthcare Life Sciences told Biopharma-Reporter.

While he said it is too early to give any specific numbers, the collaboration is expected to lead to significant cost and time-saving opportunities for GE’s biomanufacturing customers.

“Our goal is to reduce the time-consuming empirical, trial and error methods required to find the most optimal production cell clone and in the future, we could have a service, where our customers can choose the most optimal cell line for their product to increase speed, quality and yield.”

The partnership comes a month after GE​ teamed up with Edinburgh, UK-based synthetic biology firm Synpromics to try and increase protein yields achieved by its CHO cell line.


The work itself will be carried out at acib, an R&D centre run by a consortium of Austrian-based universities and the non-academic Styrian Joanneum Research institute and funded by both industrial and public contributions.

“It is very important to find world class partners that can bring the right competence to these types of collaborative efforts with the end goal to deliver valuable solutions for our customers,”​ Norris said.

“We are keen to team up with acib, because it is a renowned institute and the team led by Nicole Borth has conducted world-leading research on how the genetic processes in the cell line work.”

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more